8-K: Amedisys Reports Mixed Third Quarter 2024 Results Amidst Pending UnitedHealth Merger

Amedisys reported a revenue increase but a slight adjusted EBITDA increase for the third quarter of 2024, while navigating merger-related expenses and a pending acquisition by UnitedHealth Group.

Summary

• Amedisys announced its financial results for the three and nine-month periods ending September 30, 2024.
• Net service revenue for the quarter increased to $587.7 million, up from $556.2 million in the same period last year.
• Net income attributable to Amedisys was $16.9 million, which includes $16.7 million in merger-related expenses, compared to $26.0 million last year, which included $5.0 million in merger-related expenses.
• Adjusted EBITDA for the quarter was $58.1 million, a slight increase from $57.9 million in the prior year.
• Adjusted net income per diluted share was $1.00, compared to $0.98 in the same quarter of 2023.
• For the nine-month period, net service revenue reached $1,750.3 million, up from $1,665.6 million in 2023.
• Net income attributable to Amedisys for the nine months was $63.6 million, including $49.2 million in merger-related expenses, compared to a net loss of $29.1 million in 2023, which included $131.2 million in merger-related expenses.
• Adjusted EBITDA for the nine-month period was $191.1 million, compared to $190.4 million in 2023.
• The company will not hold a quarterly earnings call due to the pending merger with UnitedHealth Group.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While revenue growth is positive, the impact of merger-related expenses and margin compression temper the overall outlook. The pending merger adds uncertainty.

Positives

• Amedisys experienced a $31.5 million increase in net service revenue for the third quarter of 2024 compared to the same period in 2023.
• The company's adjusted EBITDA saw a slight increase to $58.1 million in the third quarter of 2024.
• Amedisys's adjusted net income per diluted share increased to $1.00 in the third quarter of 2024.
• The company's net service revenue for the nine-month period increased by $84.7 million compared to the same period in 2023.
• Amedisys's net income for the nine-month period was $63.6 million, a significant improvement from a net loss in 2023.
• Home Health same store admissions grew by 12% in the third quarter.
• High Acuity Care admissions saw a substantial increase of 51% in the third quarter.
• Amedisys maintains a strong quality rating with a 4.24 STARS score and 89% of care centers at 4+ Stars.
• The company's free cash flow was $95.2 million for the quarter.
• The company's net leverage ratio is 0.6x.

Negatives

• Net income attributable to Amedisys was impacted by $16.7 million in merger-related expenses in the third quarter of 2024.
• The company's adjusted EBITDA margin decreased by 50 basis points to 9.9% in the third quarter.
• Home Health gross margin decreased from 43.1% to 40.7% year-over-year.
• Hospice admissions decreased by 4% on a same store basis.
• The company experienced a $7.2 million increase in total G&A expenses year-over-year.
• Home Health Medicare revenue per episode increased by only 0.2%.

Risks

• The pending merger with UnitedHealth Group could cause disruption in patient, payor, provider, referral source, supplier, management, and employee relationships.
• There is a risk that the merger agreement with UnitedHealth Group could be terminated or not completed on the anticipated terms and timetable.
• Regulatory approvals for the merger may be delayed or not obtained, or may be subject to unanticipated conditions.
• The company faces risks related to changes in Medicare and other medical payment levels.
• Staffing shortages driven by the competitive labor market could impact operations.
• The company's ability to maintain or establish new patient referral sources is a risk.
• Changes in or failure to comply with existing federal and state laws or regulations could impact the business.
• The company is exposed to business disruptions due to natural or man-made disasters, climate change, or acts of terrorism.
• The company's ability to integrate, manage, and keep its information systems secure is a risk.
• The company is exposed to the impact of inflation.

Future Outlook

The company is not providing forward-looking statements or guidance due to the pending merger with UnitedHealth Group.

Management Comments

• Amedisys will not conduct a quarterly earnings call to discuss the third quarter results due to the pending merger with UnitedHealth Group.

Industry Context

The home health and hospice industry is facing increasing regulatory scrutiny and reimbursement changes, as well as competitive pressures in the labor market. Amedisys's results reflect these challenges, with increased costs impacting profitability despite revenue growth. The pending merger with UnitedHealth Group is a significant event that could reshape the competitive landscape.

Comparison to Industry Standards

• Amedisys's Home Health same store admission growth of 12% is strong compared to industry averages, which have been experiencing slower growth.
• The company's Hospice same store average daily census growth of 0.5% is below the industry average, which has been experiencing moderate growth.
• Amedisys's High Acuity Care admissions growth of 51% is significantly higher than industry averages, indicating a strong performance in this segment.
• The company's 4.24 STARS score is above the industry average, indicating a strong focus on quality of care.
• Competitors such as LHC Group and Encompass Health have also reported similar challenges with labor costs and reimbursement pressures, but Amedisys's merger with UnitedHealth Group sets it apart from these companies.
• The company's net leverage ratio of 0.6x is relatively low compared to some of its peers, indicating a strong financial position.

Stakeholder Impact

• Shareholders may experience uncertainty due to the pending merger, but the potential for long-term value creation exists.
• Employees may experience changes in their roles and responsibilities as the company integrates with UnitedHealth Group.
• Patients should continue to receive high-quality care, but may experience changes in service delivery as the company integrates with UnitedHealth Group.
• Suppliers and creditors may experience changes in their relationships with the company as it integrates with UnitedHealth Group.

Next Steps

• The company will continue to operate under the terms of the merger agreement with UnitedHealth Group.
• Amedisys will focus on integrating its operations with UnitedHealth Group after the merger is completed.
• The company will continue to monitor and adapt to changes in the regulatory and reimbursement landscape.
• Amedisys will continue to focus on improving its quality scores and patient satisfaction.

Key Dates

Keywords

Amedisys, Home Health, Hospice, High Acuity Care, Merger, UnitedHealth Group, Financial Results, EBITDA, Revenue, Healthcare, Medicare, Earnings, Adjusted Net Income, Admissions, Quality Scores